Qaiser Shafiq, MD
Interventional Cardiology · Southgate, MINPI 1225294168
Payments from drug & device makers
Across 762 payments — averaging $1756.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1M
- Amgen$70K
- Alnylam Pharmaceuticals Inc.$66K
- Johnson & Johnson$42K
- AstraZeneca$32K
- Novartis$29K
- plus $82K from 46 others
Across 2 payments — averaging $149,131 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$298K
What the payments were for
- Consulting fees$4,0806%
- Speaking & faculty fees$42,67563%
- Travel & lodging$8,57313%
- Food & beverage$12,09718%
- Education$3541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$41,405
- Advisa$2,406
- AVEIR$1,704
- PASCAL$1,258
- FLOWTRIEVER CATHETER, S$1,204
- TEGSEDI$1,050
- (0792) MM IVUS Other$1,026
- CT THROMBECTOMY SYSTEM KIT$1,000
- Lasers$712
- Omnilink Elite vascular stent system$668
- Micra$245
- Carto 3$146
- AMPLATZER$127
- Azur CX Detachable$125
- Assure WCD$104
- ILAB$101
How this compares
$1,338,738 in reported general payments places this provider in the 95th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 483 | $513,367 |
| EntrestoSacubitril/Valsartan | 352 | $464,836 |
| UptraviSelexipag | 12 | $257,960 |
| JardianceEmpagliflozin | 145 | $173,604 |
| XareltoRivaroxaban | 120 | $139,166 |
| Repatha SureclickEvolocumab | 114 | $119,619 |
| FarxigaDapagliflozin Propanediol | 55 | $61,357 |
| MultaqDronedarone Hcl | 39 | $50,387 |
| VerquvoVericiguat | 18 | $28,975 |
| BrilintaTicagrelor | 15 | $13,197 |
| Atorvastatin Calcium | 687 | $10,441 |
| Colchicine | 170 | $9,096 |
| ClopidogrelClopidogrel Bisulfate | 472 | $8,507 |
| Metoprolol Succinate | 436 | $7,398 |
| Prasugrel Hcl | 103 | $6,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $263 | $513,367483 claims |
| NovartisEntresto | $29,093 | $464,836352 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $291 | $257,96012 claims |
| Boehringer IngelheimJardiance | $22,452 | $173,604145 claims |
| Johnson & JohnsonXarelto | $42,396 | $139,166120 claims |
| AstraZenecaFarxiga, Brilinta | $31,968 | $74,55470 claims |
| Sanofi-aventis U.S. LLCMultaq | $253 | $50,38739 claims |
| MerckVerquvo | $348 | $28,97518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Southgate
- Amir KakiDetroit$2.3M
- William MerhiGrand Rapids$2M
- Shukri DavidSouthfield$1.6M
- Marcel ZughaibSouthfield$1.2M
- Jason RicciPetoskey$1.1M
- Khaldoon AlaswadDetroit$1.1M
- Paul GrossmanAnn Arbor$1.1M
- Tamam MohamadDetroit$960K
- Harry ColferPetoskey$940K
- Araya NegashGrand Rapids$808K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.